Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer

MET inhibition is effective in some MET-amplified esophagogastric cancer (EGC) patients, but understanding acquired and de novo resistance mechanisms will be critical to improving therapy. We identified KRAS mutation as a novel cause of acquired resistance in a patient after a two-year response to M...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Discov
Hlavní autoři: Kwak, Eunice L., Ahronian, Leanne G., Siravegna, Giulia, Mussolin, Benedetta, Godfrey, Jason T., Clark, Jeffrey W., Blaszkowsky, Lawrence S., Ryan, David P., Lennerz, Jochen K., Iafrate, A. John, Bardelli, Alberto, Hong, Theodore S., Corcoran, Ryan B.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670804/
https://ncbi.nlm.nih.gov/pubmed/26432108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0748
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky